Clinical studies indicate elevated serum Cav-1 levels in non-alcoholic fatty liver disease (NAFLD) patients, accompanied by cell-type-specific expression patterns, hepatocyte Cav-1 downregulation contrasts with macrophage-specific upregulation in vivo. The gene discussed is CAV1; the disease is metabolic dysfunction-associated steatotic liver disease.